UBS Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $53
UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $53.
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating